应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BLLN BillionToOne, Inc.
盘后交易 05-28 17:52:25 EDT
97.80
+6.78
+7.45%
盘后
97.81
+0.01
+0.01%
16:40 EDT
最高
99.87
最低
88.01
成交量
68.49万
今开
90.48
昨收
91.02
日振幅
13.03%
总市值
44.98亿
流通市值
8.07亿
总股本
4,599万
成交额
6,636万
换手率
8.30%
流通股本
825.37万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
异动解读 | 古根海姆上调目标价至120美元,BillionToOne盘前大涨6.12%
异动解读 · 05-13
异动解读 | 古根海姆上调目标价至120美元,BillionToOne盘前大涨6.12%
异动解读 | 获摩根大通上调目标价,BillionToOne盘中大涨13.02%
异动解读 · 05-08
异动解读 | 获摩根大通上调目标价,BillionToOne盘中大涨13.02%
异动解读 | BTIG下调目标价,BillionToOne盘中大跌5.15%
异动解读 · 05-07
异动解读 | BTIG下调目标价,BillionToOne盘中大跌5.15%
异动解读 | 获摩根大通上调目标价,BillionToOne盘前大涨8.29%
异动解读 · 05-07
异动解读 | 获摩根大通上调目标价,BillionToOne盘前大涨8.29%
财报前瞻|BillionToOne, Inc.本季营收预计9,688.50万美元,看多为主
财报Agent · 04-29
财报前瞻|BillionToOne, Inc.本季营收预计9,688.50万美元,看多为主
Billiontoone任命陈艾伦博士为肿瘤学医学事务与临床开发副总裁
美股速递 · 04-02
Billiontoone任命陈艾伦博士为肿瘤学医学事务与临床开发副总裁
异动解读 | 遭两家机构下调目标价,BillionToOne盘中大跌5.91%
异动解读 · 03-05
异动解读 | 遭两家机构下调目标价,BillionToOne盘中大跌5.91%
财报前瞻 |BillionToOne, Inc.本季度营收预计持平,机构观点偏乐观
财报Agent · 02-25
财报前瞻 |BillionToOne, Inc.本季度营收预计持平,机构观点偏乐观
Billiontoone宣布选用Northstar Select®作为国立癌症研究中心东医院Lc-Scrum-TRY临床研究新型液体活检检测方案
美股速递 · 01-06
Billiontoone宣布选用Northstar Select®作为国立癌症研究中心东医院Lc-Scrum-TRY临床研究新型液体活检检测方案
BillionToOne超灵敏液体活检技术 为日本耐药非小细胞肺癌患者拓宽精准医疗通路
美股速递 · 01-06
BillionToOne超灵敏液体活检技术 为日本耐药非小细胞肺癌患者拓宽精准医疗通路
加载更多
公司概况
公司名称:
BillionToOne, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
BillionToOne, Inc.于2016年作为特拉华州公司开始运营。该公司开发了一种革命性的单分子下一代测序(smNGS)平台,能够以单分子灵敏度检测和精确量化基因靶标。这项创新的核心是其专利的定量计数模板(QCT),该模板可在单个DNA分子水平上进行测量。这项技术突破了医疗保健领域在检测游离DNA中稀疏但具有临床意义的疾病信号方面的一个关键瓶颈。BillionToOne的技术平台已成功应用于一系列开创性的产前和肿瘤学产品,这些产品仅需简单的血液样本即可提供可操作的诊断信息。
发行价格:
--
{"stockData":{"symbol":"BLLN","market":"US","secType":"STK","nameCN":"BillionToOne, Inc.","latestPrice":97.8,"timestamp":1779998400000,"preClose":91.02,"halted":0,"volume":684889,"hourTrading":{"tag":"盘后","latestPrice":97.81,"preClose":97.8,"latestTime":"16:40 EDT","volume":32,"amount":3129.52992,"timestamp":1780000800140,"change":0.01,"changeRate":0.000102,"amplitude":0.000409},"delay":0,"changeRate":0.07448912326961109,"floatShares":8253720,"shares":45994800,"eps":0.784214,"marketStatus":"盘后交易","change":6.78,"latestTime":"05-28 17:52:25 EDT","open":90.48,"high":99.87,"low":88.01,"amount":66355340.63609,"amplitude":0.130301,"askPrice":100,"askSize":21,"bidPrice":95.1,"bidSize":20,"shortable":3,"etf":0,"ttmEps":0.784214,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1780012800000},"marketStatusCode":4,"adr":0,"listingDate":1762405200000,"exchange":"NASDAQ","adjPreClose":91.02,"preHourTrading":{"tag":"盘前","latestPrice":92,"preClose":91.02,"latestTime":"09:25 EDT","volume":378,"amount":34774.87734,"timestamp":1779974715911,"change":0.98,"changeRate":0.010767,"amplitude":0.047242},"postHourTrading":{"tag":"盘后","latestPrice":97.81,"preClose":97.8,"latestTime":"16:40 EDT","volume":32,"amount":3129.52992,"timestamp":1780000800140,"change":0.01,"changeRate":0.000102,"amplitude":0.000409},"volumeRatio":1.045346,"impliedVol":0.6854,"impliedVolPercentile":0.0294},"requestUrl":"/m/hq/s/BLLN","defaultTab":"news","newsList":[{"id":"1184688689","title":"异动解读 | 古根海姆上调目标价至120美元,BillionToOne盘前大涨6.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1184688689","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184688689?lang=zh_cn&edition=full","pubTime":"2026-05-13 20:19","pubTimestamp":1778674751,"startTime":"0","endTime":"0","summary":"生物技术公司BillionToOne, Inc.(股票代码:BLLN)今日盘前股价大幅上涨6.12%,引起了市场的广泛关注。消息面上,古根海姆(Guggenheim)分析师将该公司的目标价从100美元上调至120美元,这一积极的评级调整提振了投资者信心,推动了股价在盘前交易时段的上涨。分析师上调目标价通常意味着对公司未来增长前景的看好,古根海姆此次上调BillionToOne的目标价,可能反映了对公司业务发展、财务状况或市场地位的积极评估,从而吸引了更多买盘入场。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BLLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133212466","title":"异动解读 | 获摩根大通上调目标价,BillionToOne盘中大涨13.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133212466","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133212466?lang=zh_cn&edition=full","pubTime":"2026-05-08 01:17","pubTimestamp":1778174274,"startTime":"0","endTime":"0","summary":"生物技术公司BillionToOne, Inc.今日盘中股价大幅上涨13.02%,引起了市场的广泛关注。消息面上,根据路透汇总的研究行动,摩根大通将BillionToOne的目标价从120美元上调至125美元。分析师上调目标价通常被视为对公司未来前景的积极看法,这可能是推动股价上涨的主要因素。与此同时,同一份研究报告也显示,另一家机构BTIG将BillionToOne的目标价从140美元下调至130美元。市场在今日盘中交易中,显然对摩根大通的上调行动给出了更积极的反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BLLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113984069","title":"异动解读 | BTIG下调目标价,BillionToOne盘中大跌5.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113984069","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113984069?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:32","pubTimestamp":1778164345,"startTime":"0","endTime":"0","summary":"BillionToOne, Inc.(BLLN)今日盘中股价大跌5.15%,引起了市场的广泛关注。消息面上,根据路透报道,华尔街分析师周四调整了对该公司的目标价。其中,BTIG将BillionToOne的目标价从140美元下调至130美元,而摩根大通则将目标价从120美元上调至125美元。市场对BTIG下调目标价的反应更为敏感,这可能是导致股价下跌的主要原因。分析师调整目标价通常反映了对公司未来业绩的预期变化,投资者据此调整持仓,从而引发股价波动。目前,市场正在消化这些新的评级信息。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BLLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186191201","title":"异动解读 | 获摩根大通上调目标价,BillionToOne盘前大涨8.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186191201","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186191201?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:07","pubTimestamp":1778152064,"startTime":"0","endTime":"0","summary":"生物技术公司BillionToOne, Inc.今日盘前股价大幅上涨8.29%,引起了市场关注。消息面上,根据路透汇总的研究行动,摩根大通将BillionToOne的目标价从120美元上调至125美元。分析师上调目标价通常被视为对公司未来前景的积极看法,这可能是推动股价上涨的主要因素。与此同时,同一份研究报告也显示,另一家机构BTIG将BillionToOne的目标价从140美元下调至130美元。市场在今日盘前交易中,显然对摩根大通的上调行动给出了更积极的反应。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BLLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147885199","title":"财报前瞻|BillionToOne, Inc.本季营收预计9,688.50万美元,看多为主","url":"https://stock-news.laohu8.com/highlight/detail?id=1147885199","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147885199?lang=zh_cn&edition=full","pubTime":"2026-04-29 14:30","pubTimestamp":1777444228,"startTime":"0","endTime":"0","summary":"BillionToOne, Inc.将于2026年05月06日发布2026年第一季度财报,市场聚焦收入延续性与利润率稳定性。当前一致预期本季度公司营收为美元9,688.50万,同比增速0.00%;调整后每股收益为0.05美元,同比增速0.00%;EBIT预计为美元301.67万,同比增速0.00%;上一季度披露中未给出本季度毛利率、净利率或归母净利润的具体预测。本季度市场预计营收为美元9,688.50万,在上一季度毛利率71.42%的基础上,若结构与成本假设大体延续,毛利规模有望受惠于量增带来的固定成本摊薄。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻|BillionToOne, Inc.本季营收预计9,688.50万美元,看多为主","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177808481","title":"Billiontoone任命陈艾伦博士为肿瘤学医学事务与临床开发副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=1177808481","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177808481?lang=zh_cn&edition=full","pubTime":"2026-04-02 21:03","pubTimestamp":1775135004,"startTime":"0","endTime":"0","summary":"Billiontoone近日宣布,正式任命陈艾伦博士担任公司肿瘤学医学事务与临床开发副总裁一职。陈博士将负责领导公司在肿瘤领域的医学战略规划、临床开发项目推进以及相关事务管理工作。此次人事任命旨在进一步加强Billiontoone在肿瘤治疗领域的专业布局,推动创新疗法的研发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLLN","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186729137","title":"异动解读 | 遭两家机构下调目标价,BillionToOne盘中大跌5.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186729137","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186729137?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:46","pubTimestamp":1772721988,"startTime":"0","endTime":"0","summary":"BillionToOne, Inc. (BLLN) 今日盘中股价大跌5.91%,引起了市场的关注。消息面上,据路透报道,华尔街分析师在周四调整了对多家美国公司的评级和目标价。其中,BTIG将BillionToOne的目标价从160美元下调至140美元,杰富瑞(Jefferies)也将该股目标价从117美元下调至92美元。两家机构同时下调目标价,可能反映了对该公司前景的谨慎看法,从而影响了市场情绪。分析师调整目标价是影响个股短期走势的常见因素。此次下调可能引发了部分投资者的抛售,导致股价在交易时段内承压下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BLLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106312764","title":"财报前瞻 |BillionToOne, Inc.本季度营收预计持平,机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1106312764","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106312764?lang=zh_cn&edition=full","pubTime":"2026-02-25 10:25","pubTimestamp":1771986330,"startTime":"0","endTime":"0","summary":"BillionToOne, Inc.将于2026年03月04日盘后发布财报,市场关注营收与利润率边际改善及调整后每股收益的变动。根据当前市场一致预期,本季度公司营收预计为8,716.09万美元,同比为0.00%;调整后每股收益预计为0.09美元,同比为0.00%,公司上一季度未披露对本季度收入的明确指引,毛利率与净利润的本季度预测数据亦未提供。上季度公司营收为8,352.30万美元,同比为0.00%;毛利率为69.94%;归属母公司股东的净利润为150.70万美元,净利率为1.80%;调整后每股收益为0.10美元,同比为0.00%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 |BillionToOne, Inc.本季度营收预计持平,机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLLN"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1197071966","title":"Billiontoone宣布选用Northstar Select®作为国立癌症研究中心东医院Lc-Scrum-TRY临床研究新型液体活检检测方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1197071966","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197071966?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:09","pubTimestamp":1767708555,"startTime":"0","endTime":"0","summary":"精准医疗企业Billiontoone近日宣布,其创新液体活检产品Northstar Select已被正式选定为国立癌症研究中心东医院开展的Lc-Scrum-TRY临床研究项目的新型检测工具。此次合作将依托Northstar Select的高灵敏度特性,对参与Lc-Scrum-TRY研究的肺癌患者进行循环肿瘤DNA监测。国立癌症研究中心东医院作为日本顶尖肿瘤研究机构,其主导的Lc-Scrum-TRY项目旨在建立肺癌治疗响应评估新范式。引入Billiontoone的液体活检技术,有望突破传统组织活检的时空局限性,实现治疗过程中肿瘤基因演变的连续追踪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BLLN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155397923","title":"BillionToOne超灵敏液体活检技术 为日本耐药非小细胞肺癌患者拓宽精准医疗通路","url":"https://stock-news.laohu8.com/highlight/detail?id=1155397923","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155397923?lang=zh_cn&edition=full","pubTime":"2026-01-06 22:07","pubTimestamp":1767708457,"startTime":"0","endTime":"0","summary":"BillionToOne公司推出的超灵敏液体活检技术,正在日本市场显著提升耐药性非小细胞肺癌患者获得精准医疗的机会。这项创新检测方法通过高灵敏度分析血液中的循环肿瘤DNA,能够精准识别对传统治疗方案产生抵抗的肺癌患者的特定基因突变,从而为临床医生制定个性化治疗策略提供关键依据。\n目前,该技术已开始在日本多家医疗机构推广应用,有望改变耐药非小细胞肺癌患者的治疗格局。与传统组织活检相比,液体活检具有创伤小、可重复性强等优势,特别适合需要长期监测治疗反应的患者群体。随着精准医疗理念的深入,这项技术将为更多日本肺癌患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLLN","BK4196"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.billiontoone.com","stockEarnings":[{"period":"1week","weight":0.0916},{"period":"1month","weight":0.1133},{"period":"3month","weight":0.2746},{"period":"6month","weight":-0.3008},{"period":"1year","weight":0.517},{"period":"ytd","weight":0.1122}],"compareEarnings":[{"period":"1week","weight":0.0124},{"period":"1month","weight":0.0493},{"period":"3month","weight":0.0887},{"period":"6month","weight":0.0981},{"period":"1year","weight":0.2695},{"period":"ytd","weight":0.1005}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BillionToOne, Inc.于2016年作为特拉华州公司开始运营。该公司开发了一种革命性的单分子下一代测序(smNGS)平台,能够以单分子灵敏度检测和精确量化基因靶标。这项创新的核心是其专利的定量计数模板(QCT),该模板可在单个DNA分子水平上进行测量。这项技术突破了医疗保健领域在检测游离DNA中稀疏但具有临床意义的疾病信号方面的一个关键瓶颈。BillionToOne的技术平台已成功应用于一系列开创性的产前和肿瘤学产品,这些产品仅需简单的血液样本即可提供可操作的诊断信息。","exchange":"NASDAQ","name":"BillionToOne, Inc.","nameEN":"BillionToOne, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BillionToOne, Inc.(BLLN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BillionToOne, Inc.(BLLN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BillionToOne, Inc.,BLLN,BillionToOne, Inc.股票,BillionToOne, Inc.股票老虎,BillionToOne, Inc.股票老虎国际,BillionToOne, Inc.行情,BillionToOne, Inc.股票行情,BillionToOne, Inc.股价,BillionToOne, Inc.股市,BillionToOne, Inc.股票价格,BillionToOne, Inc.股票交易,BillionToOne, Inc.股票购买,BillionToOne, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BillionToOne, Inc.(BLLN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BillionToOne, Inc.(BLLN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}